[{"orgOrder":0,"company":"Zelluna Immunotherapy","sponsor":"Lion TCR","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zelluna Collaborates with Lion TCR to Develop TCR-NK Cell Therapies to Treat Virally Induced Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"NORWAY","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Zelluna Immunotherapy"},{"orgOrder":0,"company":"Targovax","sponsor":"Agenus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Targovax ASA and Agenus Announce Collaboration on Mutant KRAS Cancer Vaccine Adjuvanted With QS-21 STIMULON\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"NORWAY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Targovax"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Under the collaboration with Targovax, Agenus will supply QS-21 STIMULON and scientific support for up to three initial TG01 clinical trials in different cancer indications.
The collaboration will initially focus on the development of TCR-NK products targeting Hepatitis B Virus (HBV) which is a leading cause of liver cancer and has a high unmet need for efficient treatment options.